Johnson Matthey has manufactured a new Gusev catalyst for ester hydrogenation using technology that promotes sustainability and improved reactivity and selectivity, according to the company.
Johnson Matthey (JM), a provider of pharmaceutical services, active pharmaceutical ingredients, and catalyst technologies, has added a new Gusev catalyst for ester hydrogenation to its product offerings.
The catalyst, Ru-SNS, uses licensed technology conceived and developed in the laboratories of Professor Dmitri Gusev of Wilfrid Laurier University in Waterloo, Ontario, Canada, and licensed to JM in 2016 by GreenCentre Canada, a provider of intellectual property services to support the development of chemistry-driven activities. The catalyst combines high activity with high chemoselectivity, providing improvements for industrial applications of ester hydrogenation. The catalyst also possesses a higher tolerance of challenging functional groups, according to the company.
The company also reports that reactions using this catalyst are safer compared to existing industrial processes, owing to the milder operating conditions, and produce less environmental waste, providing economic and environmental performance improvement for various large-scale commercial chemical processes.
Source: Johnson Matthey
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.